Neoplasms, Connective Tissue: Clinical Trials

408 trials for Neoplasms, Connective Tissue, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

193 completed, 76 recruiting, 52 terminated, 33 active not recruiting. 408 Phase 1, 137 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1408Completed 193, Recruiting 76, Terminated 52, Active not recruiting 33, Unknown 20, Not yet recruiting 14, Withdrawn 14, Suspended 5, Enrolling by invitation 1
Phase 2137Completed 53, Recruiting 28, Terminated 18, Active not recruiting 14, Unknown 13, Not yet recruiting 7, Withdrawn 2, Enrolling by invitation 1, Suspended 1

Follow Neoplasms, Connective Tissue: new trials by email Literature Review of Neoplasms, Connective Tissue trials Research Report on Neoplasms, Connective Tissue

Trials (filtered) newest first · largest first

All 408 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin) - Neuroblastoma (NBL), Ewing Sarcoma
Phase 1Not yet recruitingUniversität Münster302027-10-012026-11-03
Combination Immunotherapy Targeting Sarcomas
Multiple sarcoma-specific CAR-T cells and sarcoma vaccines - Sarcoma, Osteoid Sarcoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202027-07-012026-11-02
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
Sarcoma-specific CAR-T cells - Sarcoma, Osteoid Sarcoma
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute202027-06-012026-10-30
SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).
ZEN003694, Radiation Therapy - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center572027-05-312026-11-18
A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat
Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm
Phase 1 / Phase 2Not yet recruitingChildren's Oncology Group792027-05-072026-09-22
A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
ST316 IV - Familial Adenomatous Polyposis (FAP)
Phase 1Not yet recruitingSapience Therapeutics402027-01-042026-08-12
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Phase 1Not yet recruitingJonsson Comprehensive Cancer Center182026-12-012026-08-06
EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT
EWSR1 immunotherapy, Pembrolizumab - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
Phase 1Not yet recruitingRabi Hanna242026-10-012026-09-17
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France892026-10-012026-10-01
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Surgical Resection, Stereotactic Body Radiation Therapy (SBRT), Atezolizumab - Osteosarcoma, Pulmonary Recurrence of Osteosarcoma
Phase 1RecruitingEmory University122026-10-012026-09-30
A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma
SOT106 - Osteosarcoma Metastatic, Soft Tissue Sarcoma (STS)
Phase 1 / Phase 2Not yet recruitingSOTIO Biotech a.s.702026-09-302026-09-03
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
TLN-499, Venetoclax - Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
Phase 1RecruitingTreeline Biosciences, Inc.1202026-08-052026-10-01
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor
BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST
Phase 1 / Phase 2RecruitingAnkit Mangla, MD172026-08-012026-08-11
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Domatinostat, Sirolimus - Sarcoma, Osteosarcoma
Phase 1 / Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute742026-07-152026-09-03
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells - Relapsed Neuroblastoma, Refractory Neuroblastoma
Phase 1RecruitingBaylor College of Medicine272026-07-152026-07-21
Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
DCC-2618 - Gastrointestinal Stromal Tumors
Phase 1RecruitingOno Pharmaceutical Co., Ltd.102026-07-072026-07-20
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
Imatinib, Fampridine - Gastrointestinal Stromal Tumors
Phase 1RecruitingUniversity of California, San Diego182026-05-132026-05-27
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Eflornithine (DFMO), AMXT 1501 Dicaprate - Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes
Phase 1 / Phase 2RecruitingMilton S. Hershey Medical Center2652026-05-132026-09-03
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine - Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 1RecruitingZelluna Immunotherapy AS92026-05-112026-09-04

Showing 20 of 408. Sign in to see all of them.

Narrower conditions

Osteosarcoma (150)  ·  Sarcoma (141)  ·  Sarcoma, Ewing (105)  ·  Neuroblastoma (86)  ·  Rhabdomyosarcoma (66)  ·  Gastrointestinal Stromal Tumors (63)  ·  Sarcoma, Synovial (58)  ·  Melanoma (50)  ·  Ovarian Neoplasms (50)  ·  Neoplasms (45)  ·  Wilms Tumor (41)  ·  Neurofibrosarcoma (35)  ·  Carcinoma, Non-Small-Cell Lung (33)  ·  Breast Neoplasms (32)  ·  Carcinoma, Hepatocellular (30)

Broader conditions

Neoplasms by Histologic Type (407)  ·  Neoplasms, Connective and Soft Tissue (405)  ·  Neoplasms (363)  ·  Neoplasms, Bone Tissue (212)  ·  Neoplasms by Site (188)  ·  Neoplasms, Glandular and Epithelial (181)  ·  Neoplasms, Nerve Tissue (169)  ·  Sarcoma (165)  ·  Neuroectodermal Tumors (141)  ·  Neoplasms, Germ Cell and Embryonal (134)  ·  Digestive System Diseases (120)  ·  Urogenital Diseases (119)  ·  Digestive System Neoplasms (118)  ·  Urogenital Neoplasms (116)

Interventions

Cyclophosphamide (33)  ·  Imatinib Mesylate (19)  ·  Irinotecan (19)  ·  Carboplatin (15)  ·  Temozolomide (15)  ·  fludarabine (14)  ·  Gemcitabine (13)  ·  Doxorubicin (12)  ·  Filgrastim (12)  ·  Leucovorin (12)  ·  Cisplatin (11)  ·  Ifosfamide (11)  ·  Paclitaxel (11)  ·  Bevacizumab (10)  ·  Etoposide (9)

Sponsors

National Cancer Institute (NCI) (45)  ·  M.D. Anderson Cancer Center (11)  ·  Memorial Sloan Kettering Cancer Center (9)  ·  St. Jude Children's Research Hospital (9)  ·  Gynecologic Oncology Group (8)  ·  Emory University (7)  ·  Children's Oncology Group (6)  ·  Deciphera Pharmaceuticals, LLC (6)  ·  Fred Hutchinson Cancer Center (6)  ·  Novartis Pharmaceuticals (6)  ·  City of Hope Medical Center (5)  ·  Dana-Farber Cancer Institute (5)  ·  Eli Lilly and Company (5)  ·  Mayo Clinic (5)  ·  Peking University People's Hospital (5)

Countries

United States (314)  ·  France (43)  ·  Spain (34)  ·  China (32)  ·  Italy (31)  ·  United Kingdom (31)  ·  Germany (28)  ·  Canada (27)  ·  Australia (26)  ·  Netherlands (19)  ·  Japan (18)  ·  South Korea (18)  ·  Belgium (13)  ·  Denmark (11)  ·  Poland (10)

Top investigators

AeRang Kim, MD, PhD (4)  ·  Holly Meany, MD (3)  ·  Jonathan Metts, MD (3)  ·  Matteo Trucco, MD (3)  ·  Peter G. Rose, MD (3)  ·  Thomas Cash, MD, MSc (3)  ·  Brigitte C Widemann, M.D. (2)  ·  Catherine Albert, MD (2)  ·  Crystal L Mackall, M.D. (2)  ·  Don Dizon (2)

Results publications

PMID 31401903, PMID 32192573, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15592836, PMID 15814645, PMID 16234526, PMID 16412499, PMID 16551859, PMID 16631245, PMID 16775235, PMID 16914576, PMID 16959305, PMID 17715389, PMID 18048828, PMID 18281544, PMID 18391430, PMID 18470481, PMID 19075272, PMID 19088049, PMID 19430790, PMID 19671873, PMID 20036194, PMID 20044751, PMID 20226028, PMID 20407240, PMID 20460632, PMID 20622000, PMID 21098399, PMID 22186789, PMID 22626269, PMID 22682017, PMID 22847809, PMID 23071222, PMID 23255417, PMID 23382028, PMID 23547655, PMID 23664013, PMID 24057647, PMID 24060561, PMID 24089446, PMID 24711551, PMID 24739759, PMID 25452614, PMID 25634727, PMID 25858498, PMID 25917459, PMID 26002753

NIH funding

U10CA027469 (8), 2023 (6), 2015 (5), U01CA069856 (5), UM1CA228823 (5), P30CA008748 (4), P30CA033572 (4), P30CA015704 (3), U01CA097452 (3), 2018 (2), 2019 (2), P30CA015083 (2), P30CA016087 (2), P30CA068485 (2), P50CA136393 (2)